Abstract
Anlotinib(Catequentinib) is an oral multi-targeted tyrosine kinase inhibitor that effectively inhibits VEGFRs, FGFRs, PGFRs, c-kit and MET. This phase III study aims to evaluate the efficacy and safety of Anlotinib or placebo plus Gefitinib in patients (pts) with untreated EGFR-mutated metastatic NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have